🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Integra LifeSciences Holdings Corporation IART R2K

Healthcare · Medical Devices · United States
https://www.integralife.com

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

READ MORE ›
$16.04
+26.70% 1Y

Market & Price

Market Cap
$1.25B
Current Price
$16.04
High / Low (52W)
$16.46 / $8.90
Beta
1.08

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
6.14
PEG Ratio
0.67
Book Value
$13.39
Price to Book
1.20
P/S
0.76
EV/EBITDA
9.81
Dividend Yield
-

Profitability & Returns

ROCE
-15.17%
ROE
-38.63%
ROA
2.54%
Profit Margin
-30.15%
Op Margin
10.41%
EPS (Latest Qtr)
$-0.06
EPS (TTM)
$-6.47

Balance Sheet & Liquidity

Debt/Equity
1.96
Quick Ratio
1.53
Current Ratio
3.38
Debt
$2.04B
Total Assets
$3.60B
Current Assets
$1.16B
Working Capital
$703.56M

Ownership

Promoter Holding
14.41%
Chg in Prom Hold
-
FII / Inst Holding
101.08%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$3.02B
Total Revenue (TTM)
$1.64B
EBITDA
$308.30M
Free Cash Flow
$69.29M
Operating Cash Flow
$71.44M
Shares Outstanding
77.80M
Gross Margin
56.72%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
1.63%
Profit 5Y
-128.69%
Revenue (YoY)
2.40%
Earnings (YoY)
-

PROS

  • Generates positive free cash flow.

CONS

  • Earnings shrank at -128.7% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IART Integra LifeSciences Holdings Corporation R2K 16.04 - $1.25B - -15.17% -38.63% 1.63% -128.69%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------258.64M282.16M278.83M368.60M357.08M366.19M365.85M383.31M359.69M383.64M379.10M395.13M354.32M258.67M370.23M388.65M360.07M389.99M386.86M376.64M397.81M385.19M380.85M381.27M382.42M368.87M418.18M380.83M382.65M415.61M402.06M434.93M391.92M
Cost of Revenue -----------------------------------188.22M206.27M195.07M214.06M174.94M
Gross Profit 137.42M140.30M151.16M152.00M159.74M161.00M170.24M172.05M183.17M177.08M220.43M212.86M228.62M222.61M236.85M230.78M239.97M236.46M245.66M220.85M153.19M235.42M241.58M------------194.43M209.33M206.99M220.87M216.98M
Operating Expenses -----------------------------------209.93M210.64M195.23M197.82M205.51M
Operating Income 24.34M9.99M-22.10M22.38M30.09M-9.96M16.98M10.64M-25.58M27.63M23.68M-32.31M45.96M-20.59M-27.10M14.08M57.54M-30.71M51.85M56.44M46.16M59.87M65.05M36.38M12.50M26.59M3.96M-3.03M-8.15M-15.50M-1.31M11.76M23.04M11.47M
EBITDA -----------------------------------25.97M-472.22M54.42M66.41M58.49M
Interest Expense -----------------------------------18.82M21.04M22.73M23.67M22.46M
Pretax Income ------------------------------------30.04M-530.95M-6.82M4.31M-2.41M
Tax Provision ------------------------------------4.74M-46.88M-1.42M6.01M2.21M
Net Income 5.00M-31.88M14.98M13.42M12.76M20.14M28.25M6.39M10.84M3.16M44.35M10.99M11.38M13.29M25.14M32.76M29.74M-27.61M15.32M9.18M-369.00K32.34M92.74M45.39M35.07M43.23M32.90M44.79M49.91M24.23M4.18M19.50M-3.28M-12.40M-10.70M-25.29M-484.07M-5.40M-1.70M-4.62M
Diluted EPS 0.08-0.450.200.180.160.250.350.080.140.040.560.140.140.150.290.380.34-0.320.180.110.000.381.090.530.410.510.390.540.600.290.050.24-0.04-0.16-0.14-0.33-6.31-0.07-0.02-0.06
R&D Expense 12.01M13.94M-14.45M14.68M15.12M-15.49M15.75M15.03M-18.32M19.11M20.31M-18.32M17.63M19.00M-20.82M14.93M-------------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------992.08M1.19B1.47B1.52B1.37B-1.56B1.54B1.61B1.64B
Cost of Revenue --------------587.36M656.84M728.47M803.62M
Gross Profit ------493.77M556.19M642.99M752.73M900.95M952.88M851.03M-970.31M884.74M882.06M831.62M
Operating Expenses --------------731.39M773.21M853.65M813.62M
Operating Income 47.41M97.82M98.69M54.91M73.78M35.37M67.86M79.59M115.34M44.80M111.00M93.76M151.37M-238.92M111.53M28.41M18.00M
EBITDA --------------381.79M255.96M193.29M-325.42M
Interest Expense --------------49.59M51.38M70.63M86.25M
Pretax Income --------------213.89M81.07M-18.24M-563.50M
Tax Provision --------------33.34M13.33M-11.29M-47.03M
Net Income 27.73M50.95M65.67M27.99M41.20M-21.07M34.00M-3.52M74.56M64.74M60.80M50.20M133.89M-180.55M67.74M-6.94M-516.47M
Diluted EPS 0.961.742.170.951.44-0.740.52-0.050.940.820.720.581.57-2.160.84-0.09-6.74
R&D Expense 60.49M44.28M48.11M51.45M51.01M42.62M43.56M50.90M58.16M63.45M78.04M-------

Compounded Sales Growth

5 Years:1.63%
1 Year:2.40%

Compounded Profit Growth

5 Years:-128.69%
1 Year:-

Stock Price Performance

1 Year:+26.70%
6 Months:+21.06%
3 Months:+40.95%
1 Month:+59.13%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --940.10M1.02B1.14B1.16B1.19B1.59B1.77B1.81B3.21B3.11B3.30B3.62B-3.89B3.78B4.04B3.60B
Current Assets ---------------1.16B1.06B1.08B1.16B
Cash & Equivalents 57.34M183.55M71.89M128.76M100.81M96.94M120.61M71.73M48.13M102.06M174.94M138.84M198.91M470.17M-456.66M276.40M246.38M235.05M
Inventory ---------------324.58M389.61M429.09M492.74M
Receivables ---------------263.46M259.33M272.37M278.85M
Total Liabilities --495.22M519.17M651.47M645.82M526.05M883.10M1.02B968.29M2.25B1.73B1.89B2.10B-2.09B2.19B2.49B2.56B
Current Liabilities --156.73M201.86M101.87M106.93M119.38M126.03M139.13M123.60M348.91M262.55M331.31M401.01M-320.91M306.98M922.13M455.98M
Long Term Debt -----------900.00M877.50M877.50M-1.41B1.49B1.20B1.73B
Total Debt ---------------1.62B1.68B1.98B2.03B
Total Equity 287.59M372.31M444.88M499.96M492.64M517.77M666.09M704.32M751.44M839.67M962.31M1.38B1.42B1.51B-1.80B1.59B1.55B1.04B
Shares Outstanding ---------------90.48M90.92M91.61M92.29M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 72.59M143.24M105.57M104.33M59.10M53.27M83.56M104.85M116.41M114.54M199.68M231.43M203.83M-264.47M139.96M129.38M50.38M
Investing Cash Flow -100.28M-88.35M-42.32M-190.38M-79.28M-50.30M-363.32M-372.01M-42.62M-1.22B-49.70M-162.67M-68.07M--58.58M-94.18M-390.81M-108.06M
Financing Cash Flow 153.54M-171.34M-1.57M60.14M11.75M19.02M238.68M248.14M-15.12M1.17B-180.87M-8.77M121.62M--251.95M-229.93M237.86M28.34M
Capital Expenditure -13.40M-25.24M-37.14M-38.42M-69.03M-42.30M-38.34M-33.41M-47.33M-43.50M-77.74M-69.54M-38.89M--47.09M-66.86M-114.37M-95.64M
Free Cash Flow 59.19M118.00M68.43M65.90M-9.93M10.97M45.23M71.44M69.08M71.04M121.94M161.90M164.94M-217.38M73.09M15.01M-45.25M
Net Change in Cash ---------------46.06M-184.15M-23.56M-29.34M
Share Buybacks 0031.28M83.46M00----00100.00M0125.00M275.00M52.47M221.00K

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------64.8%63.3%61.2%62.8%62.0%-62.3%57.4%54.8%50.9%
Operating Margin % --------11.6%3.8%7.5%6.2%11.0%-15.3%7.2%1.8%1.1%
Net Margin % --------7.5%5.4%4.1%3.3%9.8%-11.6%4.4%-0.4%-31.6%
ROE % 7.4%11.5%13.1%5.7%8.0%-3.2%4.8%-0.5%8.9%6.7%4.4%3.5%8.8%-10.0%4.3%-0.4%-49.5%
ROCE % -12.5%12.1%5.3%7.0%3.3%4.6%4.9%6.8%1.6%3.9%3.2%4.7%-6.7%3.2%0.9%0.6%

Shareholding Pattern

Insiders
14.41%
Institutions
101.08%
Public Float
118.10%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 13.26% 10.32M $165.52M
2 Rubric Capital Management LP 9.97% 7.75M $124.37M
3 Paradigm Capital Management 5.16% 4.01M $64.36M
4 Vanguard Portfolio Management LLC 4.74% 3.69M $59.13M
5 Morgan Stanley 4.61% 3.58M $57.49M
6 Fuller & Thaler Asset Management Inc. 4.54% 3.53M $56.61M
7 Invesco Ltd. 4.48% 3.49M $55.91M
8 Vanguard Capital Management LLC 3.72% 2.89M $46.37M
9 State Street Corporation 3.71% 2.89M $46.30M
10 Dimensional Fund Advisors LP 3.57% 2.77M $44.51M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IART

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks